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1,5-benzodiazepine and group 12 dihalides:
synthesis, spectral and XRD structural studies
and theoretical calculations†
Nuria A. Illán-Cabeza,a Sonia B. Jiménez-Pulido,a Francisco Hueso-Ureña,a
Tomás Peña-Ruiz,b Miguel Quirós-Olozábalc and Miguel N. Moreno-Carretero*a
2,4-Bis(1,3,7-trimethyl-pteridine-2,4(1H,3H)-dione-6-yl)-2,3-dihydro-2-methyl-1H-1,5-benzodiazepine
(DLMBZD) has been prepared and its molecular and crystal structures have been determined from spectral
and XRD data. The benzodiazepine ligand was reacted with zinc(II), cadmium(II) and mercury(II) chloride,
bromide and iodide to give complexes with general formula [M(DLMBZD)X2]. The complexes have been
synthesized and characterized by IR, NMR and elemental analysis. The structure of seven complexes has
been obtained by single crystal X-ray diffraction. In all the cases, the metal is (2 + 2 + 1)-five-coordinated
by two halide ligands, two nitrogen atoms from pyrazine and diazepine rings and a carbonyl oxygen
from a pteridine ring. The coordinated-metal environment is a square-based pyramid, with increasing tri-
gonality from Hg(II) to Zn(II) complexes. To coordinate the metals, the ligand folds itself, establishing four
intramolecular σ–π interactions with the pyrimidine and pyrazine rings. A topological analysis of the
electron density using the Quantum Theory of Atoms in Molecules and the complexes stability has been
performed.
Introduction
Benzodiazepines (BZDs) are psychoactive drugs whose core
chemical structure is the fusion of a benzene ring and a
diazepine ring. The first benzodiazepine, chlordiazepoxide
(Librium), was discovered accidentally by Leo Sternbach in
1955 and made available in 1960 by Hoffmann La Roche,
which has also marketed diazepam (Valium) since 1963.1 The
medicinal and pharmacological relevance of the benzo-
diazepine family explains the interest in exploring their activity
such as anticonvulsant, antianxiety, analgesic, hypnotic, anti-
inflammatory, anti-depressive, anti-ulcerative, anti-allergic,
antihistaminic, and antipyretic activities2–4 and are considered
as “privileged scaffolds” in medicinal chemistry.5
Benzodiazepine has a traditional place in antiepileptic
therapies. The clinical use of BZDs can be divided into two cat-
egories. First, they are useful in the acute treatment of seizures
as drugs of choice in status epilepticus and also in some
febrile seizures. Second, the BZDs are useful in long-term
therapy of certain seizures, primarily in the pediatric
population.6
However, the biological activity is highly dependent on the
nature of the BZD scaffold including the conformation of
the 1,4-diazepine ring and its substituents, the propensity
of the hydrogen bond donor and acceptor, and the electro-
static profile.7 Consequently, the development of expedient
synthetic approaches to access new BZD scaffolds has attracted
considerable attention in the discovery of biologically active
compounds.8
The compounds with a 1,5-benzodiazepine scaffold
have recently received growing attention because of their
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pharmacological properties.9,10 There are some differences
between the effects of 1,5- and 1,4-benzodiazepines. A greater
therapeutic potential and lower incidence of side effects were
described for 1,5-BZDs when compared to 1,4-BZDs. 1,5-
Benzodiazepines exert a biological activity similar to well-
known 1,4-derivatives11 and their ring system has demon-
strated wide utility not only in central nervous system (CNS)-
drug design, but also as peptidomimetic scaffolds and key
intermediates for the preparation of other fused ring com-
pounds.12 Beside this, 1,5-benzodiazepines show anti-
microbial,13 antifeedant,14 anti-inflammatory and analgesic,15
and anticonvulsant activities.16
Several representative medicinal candidates containing a
1,5-benzodiazepine scaffold are exemplified in Scheme 1
including compounds a and b,17 two drugs for the treatment
of schizophrenia, and compound c,18 an inhibitor of HIV-1
capsid assembly.
However, interactions between these drugs and metal ions
have been scarcely investigated.19 Thus, a survey through the
Cambridge Structural Database (webCSD service, updated Jun
2016) led us to only seven examples in which the 1,5-diazepine
moiety is coordinated to a metal,20 usually as a monodentate
N-ligand,20d,e,f,g sometimes behaving as a bridging ligand,20a,b
and only one example of N,N′-bidentate behaviour.20c The
changes induced in a benzodiazepine molecule by complexa-
tion may actually be reflected in the pharmacological pro-
perties of the substance and therefore such studies might help
in elucidating the relationship between the chemical and
pharmacological properties of these drugs. Nonetheless, to
date, very few complexes of benzodiazepines have been charac-
terized unambiguously.21
In this way, our efforts are focused on the design of poten-
tial bifunctional chelator ligand systems for use as potential
drugs. So, we have recently started to study the interactions
between benzodiazepines and metals mainly with reference to
the synthesis and stereochemistry of the metallated species.
Thus, in this work, the interactions of several zinc(II),
cadmium(II) and mercury(II) halides with a new 1,5-benzo-
diazepine, in particular, with 2,4-bis(1,3,7-trimethyl-pteridine-
2,4(1H,3H)-dione-6-yl)-2,3-dihydro-2-methyl-1H-1,5-benzo-
diazepine (Scheme 2) have been reported. Both the ligand and
complexes were characterized using elemental analysis, FT-IR,
solution 1H, and 13C{1H} NMR spectroscopies, and single-
crystal X-ray crystallography. The second part of this work has
been devoted to the theoretical characterization of the nature
of the metal–ligand interactions, also including those respon-
sible for the stereochemical changes of the BZD moiety on
coordination.
Results and discussion
Synthesis and structure of the ligand
The new ligand 2,4-bis(1,3,7-trimethyl-pteridine-2,4(1H,3H)-
dione-6-yl)-2,3-dihydro-2-methyl-1H-1,5-benzodiazepine, here-
after denoted as DLMBZD (Scheme 2), has been synthesized in
two steps starting with the synthesis of the proligand 6-acetyl-
1,3,7-trimethyllumazine (DLMAceM) following a well-known
procedure.22 The available 6-acetyl group allows for a classic
condensation to isolate new multifunctional ligands con-
taining the azomethine CvN bond. Benzodiazepines are
generally synthesized by the condensation of o-phenylene-
diamine (OPDA) with α,β-unsaturated carbonyl compounds,
β-haloketones, or with ketones using acidic catalysts which are
critical to enhance the condensation process.23
Herein, the benzodiazepine-derived ligand was obtained by
refluxing in DLMAceM and o-phenylendiamine (2 : 1) in absol-
ute ethanol for 24 h with addition of a small amount of acetic
acid as a catalyst (yield ca. 70%). In the second step, a red
solid, identified as 6-[N-(2-aminophenyl)ethanimidoyl]-1,3,7-
trimethylpteridine-2,4(1H,3H)-dione (DLMOfen), was obtained.
The identification and characterization of the title ligand
DLMBZD was carried out using elemental and thermal ana-
lyses, and spectroscopic methods such as IR, 1H, and 13C NMR
spectroscopy (including HMBC and HMQC experiments).
Recrystallizing the compound DLMBZD in acetonitrile led us
to obtain crystals suitable for X-ray diffraction.
The single crystal XRD measurements indicate the presence
of a racemate because of the centrosymmetric space group, but
the asymmetric residual unit (ARU) also contains two different
DLMBZD molecules with opposite chirality, although they are
not enantiomers; thus, there are two slightly different R–S
pairs. A view of the molecular structure of the S-molecule is
depicted in Fig. 1.
Both molecules in the ARU are very similar, showing no
noteworthy geometrical features. In the pteridine moieties, the
pyrimidine and pyrazine rings are roughly coplanar with di-
hedral angles ranging from 1.9(2) to 5.5(2)° and both pteridine
Scheme 1 Representative medicinal candidates containing the 1,5-
benzodiazepine scaffold.
Scheme 2 Structure of 2,4-bis(1,3,7-trimethyl-pteridine-2,4(1H,3H)-
dione-6-yl)-2,3-dihydro-2-methyl-1H-1,5-benzodiazepine (DLMBZD).
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mean planes are angled by 166.8(4) and 153.9(4)°. The diaze-
pine rings are in a boat conformation (ca. 7% chair) with the
C62 atom at the prow and the C1F/G–C2F/G bond at the
poop.24 The successive refinement cycles allowed us to locate
the H atoms bound to nitrogen in the atoms N2F and N2G,
being involved in an intramolecular N2–H⋯N5 H-bond (see
Table S-01†). Moreover, the distances of C–N on both benzo-
diazepine nitrogen atoms clearly support the corresponding
sp2 (N1F/G) and sp3 (N2F/G) hybridizations: N1F–C1F,
1.409(4); N1G–C1G, 1.391(4); N1F–C61B, 1.286(4); N1G–C61D,
1.291(4); N2F–C2F, 1.402(4); N2G–C2G, 1.416(4); N2F–C61A,
1.474(4); N2G–C61C, 1.469(4) Å.
In the crystal structure, despite the fact that the water
molecule was refined into three different positions (site
occupation factors 55, 35 and 10%), very high thermal para-
meters indicating a high disorder were found. Also, PLATON
found a number of short π–π ring and two σ–π carbonyl–
pyrazine intermolecular interactions, as given in the ESI
(Table S-01†).25
The FT-IR spectrum exhibits a medium absorption band at
ca. 3317 cm−1 assignable to the N–H stretching vibration of
the diazepine group. The characteristic bands of the lumazine
skeleton are: the carbonyl groups of both lumazines can be
seen by two medium bands at 1723 and 1695 cm−1 and two
strong bands at 1678 and 1670 cm−1. The higher is mainly due
to ν(C2vO) and the other one may be assigned to ν(C4vO).
The band at 1555 cm−1 is attributed to ν(CvN) of the pyrazine
ring and the two bands at 1455 and 1288 cm−1 could be
assignable to ν(CvC) + ν(C–N) vibrations.26
The assignment of NMR resonances was made using pre-
viously reported data27 and the combination of HMBC and
HMQC experiments allowed the unequivocal assignment of
every carbon signal. The 1H NMR spectrum of the DLMBZD
in DMSO-d6 showed δ 7.10 (m, C3F/C4F/C6F); 7.07 (s, N2F–
H), 6.67 (m, C5F), 4.27, 2.93 (dd, C62B), 1.76 (s, C62A) and
three couples of signals at 3.57/3.42, 3.35/3.14 and 2.79/
2.41 ppm are assigned to the hydrogens of the methyl
groups C3, C1 and C71 present in both lumazine moieties,
respectively.
Crystal structure and spectral studies of the complexes
The coordination chemistry of the ligand towards several zinc(II),
cadmium(II) and mercury(II) perchlorate and dihalide salts
was studied. The reactions of the DLMBZD ligand with one
equivalent of the corresponding salt in acetonitrile, ethanol or
dichloromethane at different temperatures afforded cleanly
the [MLX2] complexes. These compounds were isolated in
good yields and were characterized by elemental analysis,
NMR spectroscopy, luminescence measurements and single-
crystal X-ray diffraction. It must be pointed out that, in order
to fulfill the coordinative capacity of the ligand, syntheses with
a higher excess of metal (M/L = 2/1) were carried out but no
different products than those reported here were found.
The structures of [MX2(DLMBZD)] compounds, where
MX2 = ZnCl2 (2), ZnBr2 (3), ZnI2 (4), CdCl2 (5), CdI2 (7), and
HgI2 (10) and the adduct 2[HgI2(DLMBZD)]·HgI2·2CH3CN (11)
were solved by means of XRD methods. A view of the
HgI2(DLMBZD) portion (10), similar to the other complexes, is
shown in Fig. 2.
The geometrical features of the coordination sphere around
the metal are given in Table 1. In all cases, the metal is (2 + 2 + 1)-
five-coordinated by two halide ligands, two nitrogen atoms
from pyrazine (N5B) and diazepine (N1F) rings and a carbonyl
oxygen (O4A) from a pteridine ring. The most important
feature is the difference between M–N and M–O bonds; M–N
bond lengths range between 2.0–2.6 Å. The M–N1 (diazepine)
bonds are 5–10% longer than those involving the pyrazine N5
nitrogen. On the other hand, O4 atoms are semi-coordinated
to metals at distances 15–30% lengthened when compared
with the M–N5 bond, which agrees with the most commonly
reported coordinative behaviour of lumazine derivatives.27 The
increasing size from Zn to Hg may explain the different shapes
of the coordination polyhedra, as measured by the Addison’s τ
(see Table 1).28 Thus, these can be described as a square-based
pyramid with decreasing trigonality from Zn (near 40% TBP)
to Hg (only <5% TBP), passing through Cd (20% TBP).
Fig. 1 ORTEP drawing for the free ligand with ellipsoids at 50% prob-
ability. Another molecule in the ARU is labelled as C/D (pteridines) and
G (benzodiazepine).
Fig. 2 ORTEP drawing for [HgI2(DLMBZD)] compound (10) (ellipsoids at
50% probability), showing the intramolecular σ–π interactions (red thin
lines). Atom labels as shown in Fig. 1 (for clarity, only a few atoms have
been labelled).
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About the stereochemistry of the molecules, all crystals are
racemates containing equimolecular quantities of molecules
with R and S forms of the ligand because compounds 2, 3, 4,
and 11 crystallize in the centrosymmetric Pbca space group,
whereas compounds 5, 7 and 10 crystallize in the polar Pna21
group.
On coordinating MX2 molecules, the free DLMBZD under-
goes drastic steric changes. The dihedron N5B–C6B–C61B–
N1F is closed from nearly 180° to 25–30° in the complexes
and the dihedron N5A–C6A–C61A–N2F is opened from
ca. 10° to 140°, the diazepine ring being flattened from a quasi-
boat (∼93%) to an intermediate boat-chair arrangement
(∼60% boat).24 Therefore, the dihedral angle between both
pteridine skeletons is closed from ca. 160° to 30–50° in the
complexes, the ligand becomes folded to establish four intra-
molecular π–π interactions between both the halogen (X2)
and carbonyl (C4AvO4A) groups and the π-cloud of the pyri-
midine and pyrazine rings of both pteridine moieties, very
important to stabilize the metal-containing molecule (see
Fig. 2). Details on these interactions, calculated using
PLATON, are given in Table S-02.† The MX2(DLMBZD) mole-
cules are linked to each other in a monodimensional
arrangement along the a (comps. 2, 3 and 4) or c (comps. 5,
7 and 10) axes, by means of N2F–H⋯X2 H-bonds with
N2F⋯X2 distances ranging from 3.4–3.8 Å (Fig. 3). Chains
are packed through other intermolecular contacts, as given in
the ESI (Table S-02†).
The compound 2[HgI2(DLMBZD)]·HgI2·2CH3CN (11) also
shows a chain-like structure following the [1 0 0] direction,
with N2F–H2F⋯O2A (1 + x, y, z) bonds (N2F⋯O2A, 3.278(9) Å)
(see Table S-02†). The ligand-free HgI2 molecules are linked to
the crystal structure mainly through weak contacts Hg2⋯I11
(−1 + x,y,z) (3.6318(9) Å), a little bit longer than the sum of
the corresponding van der Waals radii. Additional Hg1⋯Hg2
(1 + x, y, z) (4.9757(9) Å) contacts found by PLATON are quite
long to be considered effective in order to contribute to the
crystal packing.
In the IR spectra of the complexes, the presence of the di-
azepine –NH group is manifested by one band of sharp and
strong intensity (3340–3380 cm−1). In all complexes, a strong
shift (ca. 20 cm−1) is observed in the band at 1695 and
1678 cm−1, with respect to their position in the IR spectrum of
the free ligand, indicating that only one lumazine is involved
in the coordination to the metal ion. The absorption band
located at 1555 cm−1, in the IR spectra of the free ligand, is
shifted (ca. 5–10 cm−1) in the complexes, indicating the involve-
ment of the N5 atom in coordination to the metal ion.41 1H,
13C and 1H-15N HMBC NMR experiments in DMSO-d6 solution
for the isolated complexes have also been performed. Within
the experimental error, the spectra of the complexes are very
similar to the free ligand’s spectrum because the coordination
through the nitrogen N5 and N1F atoms does not lead to elec-
tronic density changes strong enough to be reflected in the
spectra; of course, the weak coordination through the carbonyl
O4 oxygen does not either.29
Table 1 Distances (Å) and angles (°) in the coordination sphere of [ZnCl2(DLMBZD)]·CH2Cl2·H2O (2), [ZnBr2(DLMBZD)]·CH2Cl2 (3),
[ZnI2(DLMBZD)]·CH3CN (4), [CdCl2(DLMBZD)] (5), [CdI2(DLMBZD)] (7), [HgI2(DLMBZD)] (10) and 2[HgI2(DLMBZD)]·HgI2·2CH3CN (11)
2 3 4 5 7 10 11
M–X1 2.221(2) 2.3268(8) 2.5153(9) 2.410(2) 2.685(1) 2.651(1) 2.6888(6)
2.5828(7)a
M–X2 2.211(1) 2.3171(7) 2.5186(8) 2.417(2) 2.701(1) 2.657(1) 2.6448(6)
M–N1F 2.186(4) 2.160(3) 2.183(5) 2.485(8) 2.484(9) 2.593(9) 2.533(5)
M–N5B 2.048(4) 2.032(3) 2.057(5) 2.277(8) 2.282(8) 2.372(9) 2.392(6)
M–O4B 2.685(5) 2.683(3) 2.752(6) 2.560(7) 2.582(7) 2.728(7) 2.752(7)
X1–M–X2 123.60(6) 124.57(3) 121.56(3) 126.73(9) 125.88(4) 135.02(4) 130.15(2)
180a
X1–M–N1F 110.4(1) 110.6(1) 115.1(1) 102.7(2) 105.7(2) 103.3(2) 106.8(1)
X1–M–N5B 111.4(1) 110.9(1) 111.6(1) 115.0(2) 116.1(2) 112.1(2) 103.8(1)
X1–M–O4B 88.8(2) 88.6(1) 87.7(2) 93.4(2) 94.4(2) 96.1(2) 93.1(2)
X2–M–N1F 104.4(1) 104.6(1) 104.3(2) 105.0(2) 103.8(2) 103.0(2) 103.0(1)
X2–M–N5B 118.5(1) 117.3(1) 117.6(1) 117.1(2) 116.5(2) 111.6(2) 124.5(1)
X2–M–O4B 85.6(2) 84.4(2) 82.7(2) 94.9(2) 93.2(2) 92.4(2) 96.7(1)
N1F–M–N5B 77.8(1) 78.1(1) 78.3(2) 69.3(3) 69.0(3) 66.9(3) 66.7(2)
N5B–M–O4B 69.4(2) 69.2(2) 68.7(2) 69.1(2) 68.6(3) 65.5(3) 64.9(2)
O4B–M–N1F 146.4(2) 146.5(1) 145.2(2) 138.4(2) 137.6(3) 132.4(3) 130.7(2)
%TBP (τ) 38% 36% 39% 19% 20% 4% 2%
a In the free HgI2 molecule.
Fig. 3 Ball and stick view from the [1 −1 0] direction of the H-bonded
chain-like structure of [CdI2(DLMBZD)] (H atoms omitted for clarity).
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The d10 metal complexes have been investigated for lumines-
cent properties and potential application as photoactive
materials. Table 2 shows the absorption and emission data of
the title compounds in CH3CN solution (10
−5 M) at room
temperature. The ligand exhibits absorption bands at 240 nm
and 330 nm due to π–π* transitions. The absorption spectra of
the complexes and DLMBZD are almost identical. In Fig. 4,
emission spectra of DLMBZD and complexes at λexc = 225 nm
are shown. To establish the origin of the emission, we investi-
gated the luminescent properties of the free ligand. It shows
two emissions at 290 and 370 nm when excited at 225 nm.
Another emission appears at 470 nm (λexc = 420 nm).
In general, the emission bands of complexes resemble
those of the free organic precursor indicating that they are all
ligand-based emissions.30 The behavior observed in the inten-
sity and energy of emissions can be probably due to the differ-
ences of anions and coordination environments around metal
ions because luminescence is closely associated with the local
environments around metal ions. The intensity of emissions is
found to be weak suggesting that the metal ion partially
quenches the emissions from the ligand except for compound
2 in which the luminescence found at 290 nm is enhanced.31
Such an effect is the highest in mercury(II) compounds as a
consequence of the heavy-atom effect.
Computational chemistry
Assessment of theoretical approaches. In order to assess the
performance of the density functionals used in this research a
two-fold strategy has been used. Thus, in the first stage, the
theoretical geometries of the complexes have been compared
to the experimental XRD data when available, i.e., for ZnCl2L,
ZnBr2L, ZnI2L, CdCl2L, CdI2L and HgI2L (for simplicity, here-
after the DLMBZD ligand will be denoted as L). The parameter
used for such a comparison has been the root mean square
deviation (RMS) of the theoretical data with respect to the
experimental ones. The RMS has been calculated per type of
internal coordinate, namely, bond lengths, bond angles and
torsion angles.
In addition, two moieties are considered, the ligand L itself
and the coordination sphere. The reason for that separation is
the structure of those moieties is estimated with a significant
difference of accuracy both experimentally and theoretically.
Hence, those geometrical parameters characterizing the
coordination sphere, which involved the transition metals as
well as the halogen atoms (Table 3, lower limit of the experi-
mental error interval), are determined with the highest accu-
racy with the XRD technique since the X-rays interact with the
electrons, so the higher the electron density the higher the
accuracy. Conversely, those atoms with the highest electron
density are the most complicated to simulate at the theoretical
level, then the accuracy for the calculated parameters of the
coordination sphere is the lowest. The contrary occurs for the
intraligand geometrical data since only second period atoms
are involved, so the experimental error is higher than that for
the coordination sphere and the theoretical one lower since
there are less layers of electrons to simulate.
Therefore, Fig. 5 shows the RMS as well as the experimental
error for intraligand bond lengths (up) and angles (down). It
can be observed that the RMSs are always lower than the
experimental error regardless of the theoretical approach
except for the bond lengths of ZnBr2L which shows a rather
low experimental error for this internal coordinate with
respect to the other complexes. Thus, as far as the bond
lengths and bond angles of the ligand are concerned the
theoretical methods simulate them within the experimental
error. The torsion angles of these complexes are estimated in
general, out of the experimental error irrespective of the
moiety considered.
Other interesting observations are that all the density func-
tionals follow a similar pattern for the different RMSs of the
intraligand bond lengths and bond angles. Hence, for bond
lengths the order of the RMSs is ‘HgI2L > ZnBr2L > CdCl2L >
CdI2L ≈ ZnI2L ≈ ZnCl2L > Ligand’ for all the theoretical







DLMBZD 1 250, 330 225, 420 290, 370, 470
2 245, 330 225, 380 290, 350, 450a
3 245, 330 225 290, 350
4 245, 330 225, 375 330, 470
5 245, 330 225, 380 290, 450a
6 245, 330 228 290a
7 245, 330 225, 380 290, 355,a 450a
8 245, 330, 400 225 No emission
9 245, 330, 400 225, 375 290, 460
10 245, 325, 400 225, 380 290, 470
a Low intensity.
Fig. 4 Emission spectra of compounds 1–10 in CH3CN solution at
room temperature (λexc = 225 nm).
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approaches but for B3LYP and B3LYP-D3 for which ZnBr2L >
HgI2L. As regards the bond angles the order is ‘HgI2L > ZnI2L
> ZnBr2L ≈ ZnCl2L > CdI2L > CdCl2L > Ligand’ but with some
minor exceptions.
As for the coordination sphere, the RMS data reported in
Table 3 show values one or two orders of magnitude higher
than the experimental error irrespective of the density func-
tional. In addition, it can be observed that ωB97XD/B3LYP is
the density functional that yields the lowest/highest RMSs for
bond lengths irrespective of the complex. Conversely, for the
bond angles almost the opposite behavior is observed. Since
one of the aims of this research is to characterize the bonding
pattern within the coordination sphere, this lack of accuracy in
the estimation of its theoretical geometry makes it necessary
to conduct further tests to determine the performance of the
density functionals. Therefore, the second stage of assessment
has been carried out by using some calculated parameters con-
cerning the coordination sphere, namely, atomic charges and
magnitudes of the electron density surface obtained under the
Atoms in Molecules (AIM) theory; for instance, the electron
density (ρ) of the Bond Critical Points (BCPs) as well as their
Laplacian (∇2ρ). These parameters have been worked out for
both the experimental geometries and the theoretical ones;
provided similar patterns of behavior for these parameters
were obtained for both types of structures, similar conclusions
could be drawn for the bonding inside the coordination
sphere (almost) irrespective of the quality of the geometry.
In this way, Table 4 reports the atomic charges obtained
within both NBO and AIM frames for the experimental and
theoretical structures of the target moiety, estimated with the
approach CAM-B3LYP/DZP-DKH//CAM-B3LYP/LANL2DZ (it
should be noted that all the theoretical approximations yield
similar values for the atomic charges, Table S-03†). Thus, only
small differences arise for the geometries that have been con-
sidered, the maximum amounting to ∼7% for the O4B atom.
Furthermore, the absolute values of the charges for the atoms
involved in the coordination sphere follow similar patterns
regardless of the geometry. For example, the order observed
for this parameter in ZnCl2L is q(Zn) > q(Cl1,Cl2) > q(N5B,N1F,
O4B) within the NBO scheme and ZnCl2L is q(Zn) > q(N5B,
N1F,O4B) > q(Cl1,Cl2)> for the AIM one independent of the
used geometry.
Moreover, Fig. 6 shows the values of the BCPs’ electron
density (up) and their Laplacian (down) for the metal–halogen
bonds (M–X) in the studied complexes with the two geometries
being tested. Hence, it is observed for the series of Zn com-
plexes as well as for the two components of the Cd one for
Table 3 Experimental error for XRD-data and theoretical RMS for bond lengths (Å) and bond angles (°) in the coordination sphere
System Exp. error, 3σ SOGGA11X CAM-B3LYP B3LYP B3LYP-D3 ωB97XD
RMS bond lengths (Å)
ZnCl2L 0.006–0.030 0.142 0.145 0.152 0.130 0.126
ZnBr2L 0.002–0.018 0.158 0.162 0.175 0.149 0.139
ZnI2L 0.003–0.045 0.163 0.170 0.180 0.148 0.141
CdCl2L 0.006–0.030 0.069 0.070 0.089 0.082 0.056
CdI2L 0.002–0.036 0.091 0.094 0.120 0.103 0.075
HgI2L 0.021–0.045 0.140 0.138 0.176 0.145 0.122
RMS bond angles (°)
ZnCl2L 0.6–2.7 5.6 5.6 5.4 5.7 5.8
ZnBr2L 0.3–1.2 6.4 6.0 5.5 6.8 6.8
ZnI2L 0.6–3.0 9.1 8.4 7.9 9.7 9.5
CdCl2L 0.6–2.1 4.6 4.6 4.4 4.9 5.3
CdI2L 0.6–2.4 7.8 7.7 7.1 10.6 11.2
HgI2L 0.6–3.0 6.2 6.0 5.7 11.8 11.7
Fig. 5 Comparison between the experimental error and the theoretical
RMS for intraligand bond lengths (Å, up) and angles (°, down). Symbols:
black points, ligand; circles, ZnCl2L; diamonds, ZnBr2L; squares, ZnI2L;
crosses, CdCl2L; triangles, CdI2L; stars, HgI2L. Experimental error 3σ (Å,
up): hyphen-double dots, ZnI2L/HgI2L; hyphen-dots, CdI2L; dots,
ZnCl2L/CdCl2L; hyphens, ZnBr2L; solid line, free ligand. Experimental
error 3σ (°, down): hyphen-double dots, ZnI2L/HgI2L; hyphens, ZnCl2L;
hyphen-dots CdI2L; dots CdCl2L; solid line, ligand/ZnBr2L.
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Exp. Geometry Theor. geometry Exp. geometry Theor. geometry Exp. geometry Theor. geometry
NBO AIM NBO AIM NBO AIM NBO AIM NBO AIM NBO AIM
ZnCl2L Zn 1.05 1.14 1.09 1.15 CdCl2L Cd 1.21 1.04 1.22 1.06 HgCl2L Hg 1.10 0.94
Cl2 −0.64 −0.79 −0.66 −0.79 Cl2 −0.69 −0.79 −0.71 −0.80 Cl2 −0.64 −0.64
Cl1 −0.63 −0.78 −0.65 −0.78 Cl1 −0.69 −0.77 −0.69 −0.77 Cl1 −0.60 −0.61
N5B −0.52 −1.06 −0.52 −1.07 N5B −0.51 −1.04 −0.51 −1.03 N5B −0.48 −1.02
N1F −0.57 −1.13 −0.54 −1.10 N1F −0.57 −1.12 −0.54 −1.11 N1F −0.53 −1.07
O4B −0.57 −1.11 −0.61 −1.06 O4B −0.60 −1.14 −0.64 −1.08 O4B −0.64 −1.06
ZnBr2L Zn 0.85 0.99 0.89 1.00 CdBr2L Cd 1.01 0.91 HgBr2L Hg 0.87 0.77
Br2 −0.54 −0.72 −0.56 −0.74 Br2 −0.60 −0.78 Br2 −0.52 −0.65
Br1 −0.53 −0.71 −0.55 −0.72 Br1 −0.58 −0.75 Br2 −0.49 −0.61
N5B −0.51 −1.08 −0.52 −1.08 N5B −0.51 −1.03 N5B −0.48 −1.03
N1F −0.57 −1.13 −0.54 −1.10 N1F −0.54 −1.11 N1F −0.53 −1.10
O4B −0.56 −1.12 −0.61 −1.05 O4B −0.64 −1.06 O4B −0.64 −1.07
Znl2L Zn 0.74 1.05 0.79 1.06 Cdl2L Cd 0.88 0.90 0.90 0.95 Hgl2L Hg 0.79 0.71 0.77 0.71
I2 −0.49 −0.76 −0.50 −0.77 I2 −0.54 −0.79 −0.55 −0.81 I3 −0.48 −0.63 −0.47 −0.64
I1 −0.47 −0.74 −0.50 −0.77 I1 −0.53 −0.80 −0.54 −0.80 I2 −0.46 −0.62 −0.45 −0.65
N5B −0.52 −1.04 −0.52 −1.01 N5B −0.51 −1.08 −0.50 −1.02 N5B −0.49 −1.02 −0.47 −0.99
N1F −0.58 −1.06 −0.55 −1.08 N1F −0.55 −1.11 −0.53 −1.10 N1F −0.55 −1.10 −0.52 −1.11








































































































































































































































































transition metal and the atoms bonded to it; the BCPs and the
atoms are joined by a Bond Path (BP) and an Interatomic
Surface (IAS) (pseudo)perpendicular to the different BPs is
found.
Fig. 6 along with the data reported in Table S-04† for all the
theoretical approaches reveal the positive values of the BCPs’
Laplacian which means that they are minima of the electron
density surface and consequently, the electron charge is
shifted towards the bonded atoms, i.e., the interaction
between the metal cation and the remaining atoms of the
coordination sphere has a non-covalent nature irrespective of
the transition metal and halogen atoms.
The previous feature is further confirmed by an analysis of
the Molecular Orbitals (MOs) for the title compounds. Thus,
Tables 5 and S-05,† reporting the composition of the MOs as a
function of the atomic orbitals (only contributions ≥0.05, i.e.
≥5% are considered), show only a few MOs involving both the
transition metal and the atoms bonded to it. In addition,
those contributions are smaller than 0.15 (15%) for either the
transition metal and/or the different atoms coordinated to it.
This feature suggests that the covalent component of the
bonding scheme for the coordination sphere is low.
Furthermore, the presence of neat electron charges both on
the transition metal and the atomic species surrounding it
suggests that the bonding within the coordination sphere is of
ionic nature (Tables 4 and S-03,† see the Population analysis
section for further explanation).
Population analysis: NBO and AIM. As it can be observed in
Tables 5 and S-03,† both schemes, NBO and AIM, are coinci-
dent, with all the theoretical approaches, allocating a positive
charge ca. +1 (a.u.) or lower on the transition metals and nega-
tive charge on the atoms surrounding it. Likewise, it is
observed that those negative charges are overestimated in AIM
with respect to NBO ones. These observations along with those
written down in the previous section lead to the conclusion
that the bonding within the coordination sphere has a strong
ionic nature.
Anyway, further and throughout the analysis of the
charge allocated on the different atoms allows us to obtain
some interesting details about the already commented
bonding pattern. Hence, focusing on the charge placed on
the transition metals and the halogen atoms, NBO and AIM
produce a somewhat complementary view of the charge dis-
tribution. For the series MCl2L/MBr2L/MI2L (M = Zn, Cd,
Hg), it is observed in Tables 5 and S-03† that the absolute
values of the NBO charges on the transition metal and the
halogen atoms decrease in the order MCl2L > MBr2L > MI2L.
The previous behavior has been already observed for the
positive value of the Laplacian at the BCPs (Fig. 6), which
determines the non-covalent character of the studied
complexes.
Therefore, within the frame of Pearson’s Hard-Soft Acid–
Base (HSAB) theory, it can be argued that the ionic character
of the M–Halogen bonds decreases as the softness of the
halogen atoms (bases) increases, and makes sense. AIM
charges fail to reproduce this behavior, since the values of the
negative charges on the halogen atoms are less sensitive to
their softness and the change for the metal charge follows the
order MCl2L > MI2L > MBr2L.
On its side, AIM describes a decrease of the positive charge
on the metals for the series ZnX2L/CdX2L/HgX2L (X = Cl, Br, I)
as their softness increases, i.e., ZnX2L > CdX2L > HgX2L, which
can be interpreted in the same terms commented on pre-
viously, and the ionic character of the complexes decreases as
the metal softness increases. However, the explanations for the
evolution of the halogen AIM charges are less simple since
their negative values slightly increase from ZnX2L to CdX2L
and then decreases to HgX2L.
Fig. 7 Topology of the CdCl2L electron density surface. Triangles:
atoms. Circles: bond critical points.
Table 5 Molecular orbitals for the coordination sphere of Zn(II) and Cd(II) complexes (CAM-B3LYP/DZP-DKH)
System MO Description System MO Description
ZnCl2L HOMO−8 Cl1 p = 0.48; Cl2 p = 0.28; Zn p = 0.07 CdCl2L HOMO−9 Cl2 p = 0.55; Cl1 p = 0.12; Cd p = 0.05
HOMO−62 Zn d = 0.25; N1F p = 0.06 HOMO−62 Cd d = 0.29; N1F p = 0.06
HOMO−65 O4B p = 0.26; Zn d = 0.12; O4B s = 0.08 HOMO−67 O4B p = 0.27; Cd d = 0.18; O4B s = 0.07
ZnBr2L HOMO−7 Br1 p = 0.37; Br2 p = 0.35; Zn p = 0.08 CdBr2L HOMO−7 Br1 p = 0.48; Br2 p = 0.30; Cd p = 0.07
HOMO−8 Br2 p = 0.41; Br1 p = 0.17; Zn p = 0.06; Zn s = 0.06 HOMO−8 Br2 p = 0.52; Br1 p = 0.12; Cd p = 0.06; Cd s = 0.06
HOMO−62 Zn d = 0.20; N1F p = 0.05 HOMO−62 Cd d = 0.38; N1F p = 0.07
HOMO−65 O4B p = 0.25; Zn d = 0.13; O4B s = 0.08 HOMO−67 O4B p = 0.28; Cd d = 0.21; O4B s = 0.07
ZnI2L HOMO−5 I1 p = 0.49; I2 p = 0.35; Zn p = 0.10 CdI2L HOMO−5 I1 p = 0.56; I2 p = 0.26; Cd p = 0.10
HOMO−8 I2 p = 0.21; I1 p = 0.12; Zn s = 0.05 HOMO−7 I2 p = 0.42; I1 p = 0.10; Cd s = 0.07; Cd p = 0.07
HOMO−65 O4B p = 0.23; Zn d = 0.17; O4B s = 0.07 HOMO−62 Cd d = 0.35; N1F p = 0.07
HOMO−67 O4B p = 0.27; Cd d = 0.22; O4B s = 0.07
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With regard to the atoms of the ligand (L) bonded to the
metals, N5B, N1F and O4B, it is observed (Tables 5 and S-03†)
that both methods exhibit a similar behavior with all the
density functionals, and almost no dependence of the negative
charge of these atomic species is observed as a function of the
halogen atom for each transition metal. In addition, only a
very slight dependence with the transition metal is observed
which suggests that the main contribution to the charge of
these atoms can be due to the chemical environment of the
ligand itself.
Finally, an interesting point to comment consists of the
fact that despite the fact that bivalent cations (Zn2+, Cd2+ and
Hg2+) were used to synthesize the target compounds, the
charge allocated on them is ca. +1 (a.u.) or lower, so it implies
electron donation from the ligand atoms bonded to them as
well as from the halogens. This feature can be analyzed
through the NBO scheme by using the second order elements
of the Fock matrix. Therefore, it can be observed in Table 6
that, as expected, the donor natural orbitals correspond to
lone pairs of the atoms linked to the transition metal.
Likewise, it is checked that the main contributions to the
stabilization of the coordination sphere are due to the
donations coming from the halogen atoms for chlorides and
bromides as well. However, for the iodides, NBO shows a dis-
crepancy with respect to the general picture here depicted that
consist of NBO yielding a covalent bond among the transition
metals and the iodine atoms. This is the reason for the lack of
contributions from the iodine atoms to the central cation
(Table 6). Anyway, considering the positive values of the
Laplacian on the BCPs for the metal–halogen bonds (Fig. 6)
joined to the low occurrence of MOs with a significant par-
ticipation of the involved atomic species, our opinion is that
NBO exaggerates the covalent character of these bonds for the
target complexes. Also, this situation can be interpreted as a
borderline case that supports the decrease of the ionic charac-
ter of the metal–halogen bonding as a function of the halogen
atom softness.
Analysis of the complexes stability. The interactions that
contribute to the stability of the studied compounds can be
divided into two groups. Of course, the main one consists of
both interactions metal–ligand (M⋯L) and metal–halide
(M⋯X). The second one is formed for those interactions of the
type halide-ligand and intraligand. Thus, three of them have
been considered in this study, two of the halide-ligand type
X1⋯H6F–C6F and X2⋯C8AAvN8A (σ–π) and one of the intra-
ligand type O4A⋯C4ABvN5B (σ–π).
In this context and within the NBO frame, Table 7 supports
the summations of the second order contributions to the Fock
matrix for each type of interaction, which allows us to do an
analysis of its relative contribution to the stability of the com-
plexes. As expected, the main contributions are due to the
metal–halide as well as metal–ligand interactions. The highest
values are obtained for M⋯X components which are com-
prised in the range of 140–250 kcal mol−1 being stronger for
M⋯Br than for M⋯Cl irrespective of the metal cation. Then,
the metal–ligand links are one order of magnitude lower in
energy than M⋯X ones with values that are included in the
interval 10–60 kcal mol−1 (an exception is the Hg⋯N1F for
which no data have been recorded). Finally, the weakest contri-
butions to the stability of the target complexes are those of the
types, halide-ligand and intraligand, and their energy range is
around 0–4 kcal mol−1. A rough estimation of the relative con-
tribution of all those interactions to the stability of the target
compounds on the basis of the NBO data yields that M⋯X
interactions contribute ∼70–85% of the stabilization energy,
M⋯L ones contribute ∼10–25% and halide-ligand/intraligand
ones contribute ∼0.5–2%.
Atoms in Molecules theory support the previous analysis of
the relative strength of the two groups of interactions. Thus,
comparing the data appearing in Table S-04† for the main
interactions, M⋯X/M⋯L, with those of Table S-06† for the
halide-ligand/intraligand contact, it is observed for the elec-
tronic density (ρ) of the BCPs that the values for the main
interactions are at least twice or three times higher than those
Table 6 NBO analysis. second order contributions to the Fock matrix (kcal mol−1). ωB97XD/DZP-DKH
Donora Acceptorb ZnCl2L ZnBr2L ZnI2L
c CdCl2L CdBr2L CdI2L
c HgCl2L HgBr2L HgI2L
c
LP(1)X1 →LP*(7)M 25.9 39.1 20.5 30.7 28.1 38.1
LP(4)X1 →LP*(6)M 88.0 104.4 71.2 89.6 127.7 171.3
LP(4)X1 →LP*(7)M 73.0 88.4 60.5 76.9 18.5 23.1
LP(1)X2 →LP*(7)M 21.1 35.3 15.6 27.5 23.8 15.0 11.2
LP(3)X2 →LP*(7)M 13.6 12.2 13.0 10.5 11.3 11.8 32.0
LP(4)X2 →LP*(6)M 83.6 98.9 62.7 80.7 113.9 158.7
LP(4)X2 →LP*(7)M 68.7 84.2 58.6 75.6 16.9 21.6
LP(1)O4B →LP*(9)M 13.6 19.3 20.8 17.2 17.7 18.5 12.4 12.7 13.6
LP(2)O4B →LP*(9)M 10.4 14.0 14.0 12.8 13.7 14.9 11.0 10.9
LP(1)N1F →LP*(6)M 21.1 21.9 12.4 12.9 13.0 10.4 13.8 13.6
LP(1)N1F →LP*(8)M 23.5 13.3 18.3 12.6 14.1 15.6
LP(1)N5B →LP*(6)M 29.0 26.8 39.0 16.8 15.4 39.4 23.6 22.3 14.5
LP(1)N5B →LP*(8)M 27.1 26.4 26.3 30.4 11.4
a LP: occupied lone pair orbital. X: Cl, Br, I. b LP*: virtual lone pair orbital. M: Zn, Cd, Hg. c Since NBO yields covalent bonding between the
metals and the iodide anions, the second order contributions for M⋯X1 and M⋯X2 have not been considered in this analysis due to their low
significance.
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for the weakest contributions. In addition, the ellipticity of the
considered BCPs for the former interactions is lower than that
of the latter interactions, which implies that the electronic
charge is more dispersed in the latter and so it points out to
their weak conditions too.
Experimental
Materials and instrumentation
All starting materials were purchased from standard commer-
cial sources and used without further purification. Solvents
were reagent-grade commercial materials and were used as
received. Elemental analyses were performed on a Thermo
Finnigan Flash 1112 Series CHNS-O microanalyser. IR spectra
were measured over the range of 4000–400 cm−1 on a Bruker
FT-IR Tensor-27 with samples prepared as KBr pellets. 1H and
13C-NMR spectra were recorded in DMSO-d6 solutions on a
Bruker AVANCE 400 spectrometer. Fluorescence excitation and
emission spectra were recorded with a Cary Elipse fluorescence
spectrophotometer in CH3CN at room temperature.
Synthesis
All manipulations were performed under aerobic conditions
using reagents (mainly from ALFA-AESAR) and solvents as
received. The proligand 6-acetyl-1,3,7-trimethyllumazine
(DLMAceM) was synthesized from 6-amino-1,3-dimethyl-5-
nitrosouracil and acetylacetone following a reported method.22
Characterization data (elemental analysis, MS, IR and NMR) fit
well with the proposed formulae and structures; for more
information, see the ESI.†
Synthesis of the ligand 2,4-bis-(1,3,7-trimethyl-pteridine-
2,4(1H,3H)-dione-6-yl)-2,3-dihydro-2-methyl-1H-1,5-benzo-
diazepine DLMBZD·12H2O (1). The preparation was carried
out by reacting o-phenylendiamine (1.08 g, 10 mmol) with the
lumazine derivative (DLMAceM) (4.96 g, 20 mmol) in ethanol
(50 mL). Acetic acid was used as a catalyst (ca. 1 mL). The
mixture was refluxed for 25 h. The ligand was filtered off and
isolated in a high yield (71%). After the main portion of
DLMBZD was isolated, a red solid, identified as 6-[N-(2-amino-
phenyl)ethanimidoyl]-1,3,7-trimethylpteridine-2,4(1H,3H)-dione
(DLMOfen), was obtained (yield ca. 12%).
Synthesis of [ZnCl2(DLMBZD)]·CH2Cl2·H2O (2). A solution of
DLMBZD·12H2O (57.8 mg, 0.1 mmol) and ZnCl2 (13.6 mg,
0.1 mmol) in dichloromethane (40 mL) was stirred for 45 min
and cooled to room temperature. The mixture was then fil-
tered, and the final product was obtained as an orange solid
(yield, 61%). Red crystals were formed after several days in a
closed container with the solution placed in a refrigerator.
Synthesis of [ZnBr2(DLMBZD)]·CH2Cl2 (3). This complex was
obtained via an analogous procedure to that described for 2,
but using zinc(II) bromide instead of ZnCl2 (yield, 82%). After
several days, X-ray quality red crystals were obtained from the
mother liquor.
Synthesis of [ZnI2(DLMBZD)]·CH3CN (4). A mixture of ZnI2
(63.8 mg, 0.2 mmol) and DLMBZD·12H2O (115.5 mg, 0.2 mmol)
in acetonitrile (30 mL) was refluxed for 14 h. The red reaction
mixture was cooled and then filtered. Red crystals of the
product slowly grew over a period of 5 days. The crystals were
collected by filtration and dried in air (yield, 64%).
Synthesis of [CdCl2(DLMBZD)] (5). To 0.2 mmol of the
ligand dissolved in CH3CN, ethanol or dichloromethane
(30 mL), was added 0.2 mmol of the corresponding halide.
The mixture was stirred for 1 h. The reaction mixture was fil-
tered off to remove the precipitate. The formed solid was
washed with ethanol, and air-dried (yield, 83%). From the
clear liquor, crystals suitable for XRD were isolated.
[CdBr2(DLMBZD)]·12CH2Cl2·H2O (6). Using the same method
as used for compound 5, an orange solid was isolated (yield,
85%).
[CdI2(DLMBZD)] (7). Using the same method as used for
compounds 5 and 6, orange crystals suitable for XRD were iso-
lated (yield, 66%).
[HgCl2(DLMBZD)]·H2O (8). HgCl2 (108.6 mg, 0.4 mmol) and
DLMBZD·12H2O (115.5 mg, 0.2 mmol) were added to 30 mL of
CH2Cl2/EtOH (3 : 1) and the resulting orange solution was
stirred for 50 min and cooled to room temperature. An orange
solid was obtained from the mother liquor, it was filtered off,
washed with ethanol and air-dried (yield, 82%).
[HgBr2(DLMBZD)]·CH2Cl2 (9). To a stirred solution
of DLMBZD·12H2O (115.5 mg, 0.2 mmol) in a mixed
CH2Cl2 : EtOH solution (15 : 5 mL) a solution of mercury(II)
bromide (144.2 mg, 0.4 mmol) in CH2Cl2 (10 mL) was added.
The resulting orange solution was stirred for 45 min and
Table 7 ωB97XD second order contributions to the Fock matrix for interaction type (kcal mol−1)
Interactions ZnCl2L ZnBr2L Znl2L
a CdCl2L CdBr2L Cdl2L
a HgCl2L HgBr2L Hgl2L
a
M⋯X2 186.9 242.9 147.4 195.2 154.6 227.2
M⋯X1 197.8 231.9 152.2 197.2 174.3 232.4
M⋯N5B 56.1 53.2 39.0 43.1 45.8 39.4 23.6 33.7 13.6
M⋯N1F 44.6 35.2 30.8 25.5 34.5 26.0 13.8 13.6 0.0
M⋯O4B 24.0 43.9 34.8 39.8 41.4 33.4 23.4 23.6 14.5
X2⋯C8AAvN8A 3.37 2.89 1.54 3.55 3.41 1.32 1.70 0.84 0.21
X1⋯H6F–C6F 2.62 2.02 2.29 2.70 1.82 1.84 1.83 0.90 0.97
O4A⋯C4ABvN5B 1.36 1.42 1.31 1.38 1.28 1.15 1.21 0.99 0.98
a Since NBO yields covalent bonding between the metals and the iodide anions, the second order contributions for M⋯X1 and M⋯X2 have not
been considered in this analysis due to their low significance.
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Table 8 Crystallographic and refinement data for DLMBZD (1), [ZnCl2(DLMBZD)]·CH2Cl2·H2O (2), [ZnBr2(DLMBZD)]·CH2Cl2 (3), [ZnI2(DLMBZD)]·CH3CN (4), [CdCl2(DLMBZD)] (5), [CdI2(DLMBZD)] (7),
[HgI2(DLMBZD)] (10) and 2[HgI2(DLMBZD)]·HgI2·2CH3CN (11)
Compound 1 2 3 4 5 7 10 11









C28H28Cl2N10O4Cd C28H28I2N10O4Cd C28H28I2N10O4Hg C28H28I2N10O4Hg·12HgI2·
CH3CN
FW (g mol−1) 577.61 774.36 878.72 949.35 751.90 934.80 1022.99 1291.24
Color. habit Colorless prism Red prism Red prism Red prism Red prism Red prism Orange prism Orange prism
Crystal size
(mm3)
0.22 × 0.20 × 0.08 0.30 × 0.23 × 0.06 0.35 × 0.26 × 0.16 0.36 × 0.26 × 0.10 0.32 × 0.14 × 0.10 0.30 × 0.20 × 0.18 0.53 × 0.23 × 0.08 0.33 × 0.31 × 0.20
Crystal system Triclinic Orthorhombic Orthorhombic Orthorhombic Orthorhombic Orthorhombic Orthorhombic Monoclinic
Space group P1̄ Pbca Pbca Pbca Pna21 Pna21 Pna21 P21/c
Unit cell
dimens. a (Å)
11.214(2) 13.269(5) 13.226(1) 13.574(1) 14.898(2) 14.988(1) 15.031(5) 11.257(2)
b (Å) 13.319(1) 17.848(4) 17.912(3) 18.296(3) 15.081(3) 15.329(4) 15.388(5) 16.968(2)
c (Å) 18.141(3) 28.167(9) 28.272(3) 28.833(5) 13.166(3) 14.063(2) 14.032(5) 19.592(2)
α (°) 93.53(1) 90 90 90 90 90 90 90
β (°) 90.17(1) 90 90 90 90 90 90 101.889(9)
γ (°) 102.74(1) 90 90 90 90 90 90 90
Volume (Å3) 2637.5(7) 6671(4) 6698(1) 7161(2) 2958(1) 3231.2(9) 3246(1) 3661.8(9)
Z 4 8 8 8 4 4 4 4
Density (calc.
Mg m−3)
1.455 1.542 1.743 1.761 1.688 1.922 2.094 2.342
μ (mm−1) 0.103 1.033 3.332 2.464 0.974 2.637 6.695 8.870
F (000) 1212 3184 3520 3736 1520 1808 1936 2396
Diffractometer Bruker Nonius Kappa CCD
Radiation Graphite-monochromated MoKα (λ = 0.71073 Å)
Temperature (K) 120(2)
θ range (°) 3.07–27.5 2.11–27.51 5.02–27.5 3.03–27.51 3.05–27.51 3.80–27.53 3.93–27.51 3.32–27.51
Index ranges −14 < h < 14 −17 < h < 17 −17 < h < 17 −15 < h < 17 −19 < h < 19 −19 < h < 17 −19 < h < 19 −14 < h < 14
−17 < k < 17 −23 < k < 23 −15 < k < 23 −23 < k < 23 −19 < k < 19 −17 < k < 18 −17 < k < 19 −22 < k < 22
−23 < l < 23 −36 < l < 36 −36 < l < 36 −37 < l < 37 −17 < l < 17 −18 < l < 18 −17 < l < 18 −25 < l < 25
Reflecs
collected
67 937 161 999 66 668 67 480 28 953 29 719 23 670 55 643
Indep./I > 2σ(I) 12 105/5758 7678/4755 7649/5563 8219/5877 6722/4981 7371/6111 7257/6089 8404/6299
Rint 0.0874 0.1459 0.0718 0.0759 0.1050 0.0604 0.0621 0.0638
Weighting scheme w−1 = σ2(Fo
2) + (xP)2 + yP (P = (Fo
2 + 2Fc
2)/3)
x/y 0.1700/0.0500 0.1000/20.0000 0.0370/36.0000 0.1035/40.1806 0.0700/0.0000 0.0755/0.0000 0.0500/2.0000 0.0400/16.0000
Data/param.
Ratio
15.4 16.8 17.7 18.8 16.5 18.1 17.9 18.8
Goodness-of-fit
on F2
1.006 1.020 1.042 1.058 0.994 0.996 0.916 1.150
R1/wR2 [I > 2σ(I)] 0.0830/0.2153 0.0688/0.1684 0.0527/0.1063 0.0524/0.1244 0.0487/0.1111 0.0404/0.0995 0.0352/0.0835 0.0376/0.0854
R1/wR2 (all
data)
0.1820/0.2867 0.1267/0.2034 0.0863/0.1196 0.0856/0.1404 0.0832/0.1288 0.0594/0.1149 0.0509/0.0936 0.0664/0.0972
Flack
parameter









































































































































cooled to room temperature. An orange solid was obtained
from the mother liquor, it was filtered off, washed with
ethanol and air-dried (yield, 52%).
[HgI2(DLMBZD)] (10). Mercury(II) iodide (90.9 mg,
0.2 mmol) was added to a solution of DLMBZD·12H2O
(115.5 mg, 0.2 mmol) in 30 mL of CH3CN and stirred at
ambient temperature for 5 h. Dark orange crystals suitable for
X-ray diffraction were obtained several days later which were
filtered off and air dried (yield, 72%). A few orange crystals
with formula [HgI2(DLMBZD)]2[HgI2]·2CH3CN (11) were
formed in a closed container with the solution placed in a
refrigerator after several days.
Crystallography
Details of the crystallographic data collection and refinement
parameters are given in Table 8. The structures were solved by
direct methods and refined using SHELXL-2014/7 32 employing
full-matrix least-squares methods on F2. Lorentz, polarization,
and multiscan absorption corrections were applied with
SADABS.33 All non-hydrogen atoms were refined with aniso-
tropic thermal parameters by full matrix least-squares pro-
cedures on F2. In the structure of the free ligand, the hydrogen
N–H atom from the benzodiazepine ring was located and
refined isotropically; other hydrogen N–H and C–H atoms in
the free ligand and complexes were also placed in idealized
positions, and treated using riding models; O–H hydrogens
were not found. All calculations and graphics were made with
PLATON and MERCURY.34
Computational details
The geometry optimization as well as the vibrational spectrum
calculation of the ligand and transition metal complexes were
conducted by using the same series of density functionals,
namely SOGGA11X,35 ωB97XD,36 CAM-B3LYP,37 B3LYP38 and
B3LYP implementing Grimme’s D3 dispersion correction
scheme with the original damping function39 (B3LYP-D3)
through empirical dispersion = gd3 command. An all electron-
DZP basis set40 was used on all atoms for calculations invol-
ving the ligand. Moreover, the LANL2DZ-ECP basis set41 was
used on all atoms for transition metal complex calculations.
As for the complexes, single point relativistic calculations were
performed in order to produce Natural Bond Analysis42 (NBO)
data and a wave function to be used in an analysis of the elec-
tronic density. Those calculations were accomplished with the
same series of density functionals commented previously
within the second order Douglas–Kress–Hall scheme.43 In
addition, the DZP–DKH basis set44 was used which is opti-
mized for relativistic calculations. Finally, the electron density
analysis was accomplished by using the Atoms in Molecules
theory45 implemented in the AIM2000 code.46
Conclusions
The zinc, cadmium and mercury complexes containing a 1,5-
benzodiazepine derived from 6-acetyl-1,3,7-trimethyllumazine
as a ligand and perchlorate, chloride, bromide and iodide
counter anions have been isolated. Metals are (2 + 2 + 1)-co-
ordinated as a square-based pyramid with increasing trigonal-
ity from Hg to Zn. The benzodiazepine ligand acts as a N,N,
(O)-tridentate chelator through nitrogen atoms from the diaze-
pine and pyrazine moieties and also, semi-coordination of an
exocyclic carbonylic oxygen can be found. To coordinate the
metal, the ligand undergoes drastic stereochemical changes,
because it has to be folded due to the interactions established
between the electronic density of pyrimidine and pyrazine
rings from the pteridine moieties with a coordinated halide
and a carbonyl group.
The analysis of the topology of the electron density surface
within the Atoms In Molecules (AIM) frame along with an ana-
lysis of the atomic charge distribution and the second order
contributions to the Fock matrix within the Natural Bond
Orbitals (NBO) scheme lead to the conclusion that the
bonding for the coordination sphere of the series of complexes
under study has mainly an ionic nature that decreases as the
softness of both the group 12 transition metals and the
halogen atoms bonded to them increase, which makes sense
in view of Pearson’s Hard-Soft Acid–Base (HSAB) theory. In
addition, the analysis of the Molecular Orbitals (MO) for the
target moiety supports the previous conclusions. All the
density functionals used in this research (SOGGA11X,
ωB97XD, CAM-B3LYP, B3LYP, and B3LYP with Grimme’s D3
dispersion correction) yield similar results and patterns of be-
havior for most of the analyzed data. A rough estimation of the
relative contribution of all those interactions to the stability of
the target compounds on the basis of the NBO data yields that
M⋯Y interactions contribute ∼70–85% of the stabilization
energy, M⋯L ones contribute ∼10–25% and halide-ligand/
intraligand ones contribute ∼0.5–2%.
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